Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Other Operating Expenses (2017 - 2021)

Historic Other Operating Expenses for Lexaria Bioscience (LEXX) over the last 5 years, with Q1 2021 value amounting to $1.5 million.

  • Lexaria Bioscience's Other Operating Expenses changed N/A to $1.5 million in Q1 2021 from the same period last year, while for Nov 2021 it was $1.5 million, marking a year-over-year increase of 340111.21%. This contributed to the annual value of -$18198.0 for FY2020, which is 10052.83% down from last year.
  • Per Lexaria Bioscience's latest filing, its Other Operating Expenses stood at $1.5 million for Q1 2021.
  • Lexaria Bioscience's 5-year Other Operating Expenses high stood at $3.4 million for Q2 2018, and its period low was -$27929.0 during Q4 2020.
  • In the last 5 years, Lexaria Bioscience's Other Operating Expenses had a median value of $748589.5 in 2017 and averaged $885610.9.
  • As far as peak fluctuations go, Lexaria Bioscience's Other Operating Expenses skyrocketed by 83488.83% in 2018, and later tumbled by 10362.91% in 2020.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Other Operating Expenses stood at $440326.0 in 2017, then increased by 24.9% to $549964.0 in 2018, then surged by 39.93% to $769583.0 in 2019, then tumbled by 103.63% to -$27929.0 in 2020, then soared by 5552.05% to $1.5 million in 2021.
  • Its last three reported values are $1.5 million in Q1 2021, -$27929.0 for Q4 2020, and -$18198.0 during Q2 2020.